Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo.

Ogasawara, Fumiya; Higuchi, Tomonori; Nishimori, Tomohiro; Hashida, Yumiko; Kojima, Kensuke; Daibata, Masanori

Ogasawara, Fumiya; Higuchi, Tomonori; Nishimori, Tomohiro; Hashida, Yumiko; Kojima, Kensuke; Daibata, Masanori.

Afiliação

Ogasawara F; Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.
Higuchi T; Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Japan.
Nishimori T; Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.
Hashida Y; Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.
Kojima K; Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.
Daibata M; Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Japan.

J Cell Mol Med ; 26(22): 5580-5589, 2022 11.

Article em En | MEDLINE | ID: mdl-36209502

Assuntos

Herpesvirus Humano 8; Linfoma Difuso de Grandes Células B; Humanos; Camundongos; Animais; Fator A de Crescimento do Endotélio Vascular/genética; Fator A de Crescimento do Endotélio Vascular/metabolismo; Bevacizumab/farmacologia; Bevacizumab/uso terapêutico; Fatores de Crescimento do Endotélio Vascular; Microambiente Tumoral

Palavras-chave

bevacizumab; effusion lymphoma; targeted therapy; vascular endothelial growth factor; xenograft model

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Herpesvirus Humano 8 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google